EDIT vs PACB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EDIT Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Editas Medicine, Inc. Common Stock (EDIT) driven by superior Growth & Margin, Options & Structure while PACB counters with relative strength in Momentum & Technical. Fundamentally, EDIT trades at N/M Forward P/E with -167.0% operating margin (+37.4% YoY revenue) versus PACB at N/M Forward P/E and -333.0% operating margin (+5.5% YoY). In options structure, EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro) against PACB sits in BREAKDOWN (47th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | EDIT Revenue | PACB Revenue | EDIT Op. Margin | PACB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $30M | $80M | -356.1% | -128.4% | PACB |
| FY2019 | $20M | $90M | -686.4% | -110.6% | PACB |
| FY2020 | $90M | $80M | -148.6% | -132.3% | PACB |
| FY2021 | $30M | $130M | -756.1% | -161.2% | PACB |
| FY2022 | $20M | $130M | -1146.3% | -239.4% | PACB |
| FY2023 | $80M | $200M | -216.6% | -166.8% | PACB |
| FY2024 | $30M | $150M | -777.2% | -308.0% | PACB |
| FY2025 | $40M | $160M | -394.9% | -346.2% | PACB |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EDIT | PACB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $336.5M | $615.1M | Larger Scale | PACB |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +37.4% | +5.5% | Higher Growth | EDIT |
| Operating Margin (TTM) Profitability | -167.0% | -333.0% | Higher Margin | EDIT |
| Net Profit Margin Profitability | -144.9% | -81.3% | Higher Margin | PACB |
| Return on Equity (ROE) Capital Efficiency | -147.4% | -929.3% | Higher ROE | EDIT |
| 52-Week Range Position Momentum | 11% ($2โ$4) | 34% ($1โ$3) | Stronger Trend | PACB |
| Beta / 30D Volatility Risk Regime | 2.32ฮฒ ยท 102% Vol | 2.27ฮฒ ยท 112% Vol | Lower Realized Risk | EDIT |
| Unified Institutional Score Composite Signal | 51.6 / 100 (HOLD) | 38.0 / 100 (SELL) | Higher Composite | EDIT |